Lenvatinib, Tislelizumab Plus Gemcitabine and Cisplatin (GPLET) in Patients With Advanced Cholangiocarcinoma
Status:
Recruiting
Trial end date:
2028-08-31
Target enrollment:
Participant gender:
Summary
Cholangiocarcinoma (CCA) is a heterogeneous group of cancers arising from the epithelial
cells of bile ducts. Because of highly aggressive malignancy, most of the patients are
diagnosed at an advanced stage and lose the chance to undergo surgery. As more effective and
novel chemotherapy, targeted therapies, and immunotherapy become available, multiple
treatments can be chosen for the patients with advanced CCA. Cytotoxic cell death during
tumor chemotherapy triggers antigen release and induces strong anti-tumor effects of T cells.
Tyrosine kinase inhibitors (TKI) can reduce the expression of PD-L1 and inhibit Treg cell
infiltration, and together with immune checkpoint inhibitors, they can relieve tumor
immunosuppressive microenvironment. Therefore,we aim to investigate the safety and efficacy
of lenvatinib, tislelizumab combined with gemcitabine plus cisplatin (GPLET) in the treatment
of advanced cholangiocarcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University